3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
NET
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
Conditions
Uterine Cervical Neoplasms
6
Carcinoma, Non-Small-Cell Lung
4
Squamous Cell Carcinoma of Head and Neck
3
Lung Neoplasms
3
Triple Negative Breast Neoplasms
2
Stomach Neoplasms
2
Neoplasm Metastasis
2
Cholangiocarcinoma
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Urothelial Bladder Carcinoma
1
Urinary Bladder Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Thymoma
1
Sarcoma
1
Recurrence
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Oligometastatic Prostate Cancer
1
Neoplasms
1
Metastatic Urothelial Cancer
1
Melanoma
1
Locally Advanced Pancreatic Cancer
1
Locally Advanced Cervical Cancer
1
Liver Neoplasms
1
Liposarcoma
1
Kidney Neoplasms
1
Gestational Trophoblastic Disease
1
Gastro-enteropancreatic neuroendocrine tumor
1
Interventions
Sunitinib
5
pembrolizumab
4
Paclitaxel
4
Carboplatin
4
Radiotherapy
3
Cyclophosphamide
3
Cisplatin
3
selinexor
2
lenvatinib
2
Taxes
2
Ramucirumab
2
Octreotide
2
N,1,4,4-tetramethyl-8-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4,5-dihydro-1H-pyrazolo(4,3-h)quinazoline-3-carboxamide
2
Methylprednisolone
2
Erlotinib Hydrochloride
2
Chemoradiotherapy
2
zimberelimab
1
saracatinib
1
regorafenib
1
epacadostat
1
envafolimab
1
belinostat
1
avelumab
1
atezolizumab
1
amrubicin
1
alovudine
1
TP protocol
1
Radiofrequency Ablation
1
Radiation Dose Hypofractionation
1
Prednisone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Thymoma
×
zimberelimab
×
Clear all
NCT06790706
2025-10-06
IMMUNORARE5
Hospices Civils de Lyon
Phase 2
Recruiting
154 enrolled